Novartis

News

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene.

News

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company has been looking

Patients

Patient engagement processes: the pharmaphorum podcast

This episode of the pharmaphorum podcast is the second in a limited series focused on patient engagement that’s being led by clinician, consultant and patient advocate, Mark Duman.

News

Mesoblast pummelled as Novartis exits COVID deal

Novartis has opted out of a collaboration with Mesoblast to develop its stem cell-based therapy remestemcel-L as a treatment for COVID-19, prompting a slump in the biotech's share price.&nb

News

Close Up Of Senior Man Suffering With Parkinsons Diesease

Novartis takes aim at risky Parkinson's target with $1.5bn U...

Novartis has licensed a potential drug for Parkinson's from Belgium's UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlie

News

Novartis may have found a buyer for Sandoz; report

Just a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there are reports that a potential buyer has already come forward.

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Patient engagement processes: the pharmaphorum podcast

Mesoblast pummelled as Novartis exits COVID deal

Novartis takes aim at risky Parkinson's target with $1.5bn U...

Novartis may have found a buyer for Sandoz; report

Roche, Viking, and Syntis showcase obesity drug candidates

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks